Royal Philips has launched the Bridge Plus Occlusion Balloon, a next-generation device aimed at controlling bleeding during rare but critical superior vena cava (SVC) tears that can occur in less than 0.5% of transvenous lead extraction (TLE) procedures. This device can deploy in under two minutes, significantly reducing blood loss by up to 90% and maintaining hemostasis for at least 30 minutes, thereby providing electrophysiology teams with crucial time to stabilize patients and prepare for surgical intervention.

The significance of Bridge Plus lies in its potential to improve survival rates during these emergencies. Clinical evidence indicates that the availability of an occlusion balloon during SVC tear events can elevate survival rates from 56.9% to 88.2%. This is particularly vital given the life-threatening nature of SVC tears, which can escalate rapidly without immediate intervention. The Bridge Plus builds on established Bridge Occlusion Balloon technology, previously used in over 50,000 procedures in the U.S., reinforcing its reliability and clinical relevance in emergency settings.

The introduction of Bridge Plus may shift current paradigms in TLE procedures by emphasizing the need for prophylactic balloon staging tailored to individual patient anatomies. This proactive approach not only enhances procedural safety but also allows for immediate deployment in cases where fluoroscopy may be compromised. As the device becomes commercially available in the U.S. and is showcased at the upcoming Heart Rhythm Society (HRS) 2026, it represents a significant advancement in the toolkit available to electrophysiology teams, ultimately aiming to enhance patient outcomes during critical emergencies.

Source: globenewswire.com